Worldwide sales rose about 18 percent to reach $8.8 billion, fueled in part by strong sales of the drug Humira, which treats rheumatoid arthritis, and a 34 percent rise in global sales of coronary stents, such as Xience. Global stent sales soared to $533 million dollars, the company said.
Abbott expects to hit its previous guidance of full-year earnings of $4.13 to $4.18 per share. The midpoint is a 12 percent increase over 2009.
Ad Statistics
Times Displayed: 40997
Times Visited: 1152 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Abbott rose 1.2 percent to reach $49.25 in recent trading.
Back to HCB News
